| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 4,044 | 3,328 | ||
| General and administrative | 3,566 | 2,898 | ||
| Loss from operations | -7,610 | -6,226 | ||
| Other income, net | 61 | 22 | ||
| Net loss | -7,549 | -6,204 | ||
| Dividend attributable to down round feature of warrants | 1,479 | - | ||
| Net loss attributable to common stockholders | -9,028 | - | ||
| Basic net loss per share | -2.23 | -8.4 | ||
| Diluted net loss per share | -2.23 | -8.4 | ||
| Weighted average number of shares outstanding, basic, total | 4,049,046 | 738,149 | ||
| Weighted average number of shares outstanding, diluted, total | 4,049,046 | 738,149 | ||
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)